Differences in Tumor‐Infiltrating Lymphocyte Counts in the Peritumoral Area in Patients Undergoing Hepatic Resection After Lenvatinib and Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma
TIL counts, including those of CD3+ and CD8+ TILs, in the peritumoral area were significantly higher after ATZ/BEV than after LEN therapy.
Authors
- Mizuki Ninomiya (ORCID: https://orcid.org/0000-0002-0742-5955)
- Takeshi Iwasaki (ORCID: https://orcid.org/0000-0001-5277-2932)
- Shohei Yoshiya (ORCID: https://orcid.org/0000-0003-4642-5058)
- Norifumi Iseda (ORCID: https://orcid.org/0000-0001-8589-0038)
- Tomoharu Yoshizumi (ORCID: https://orcid.org/0000-0002-4497-1816)
- Shinji Itoh (ORCID: https://orcid.org/0000-0003-0382-2520)
- Yoshinao Oda (ORCID: https://orcid.org/0000-0001-9636-1182)
- Yuki Nakayama
- Takeo Toshima (ORCID: https://orcid.org/0000-0003-4019-8288)
- Katsuya Toshida (ORCID: https://orcid.org/0000-0002-4158-3287)
- Takuma Izumi (ORCID: https://orcid.org/0000-0002-9117-0560)
- Yasushi Tanaka (ORCID: https://orcid.org/0009-0000-1895-9226)
- Takuma Ishikawa
- Yuriko Tsutsui
Institutions
- Kyushu University (JP)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/cam4.70445
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00